Wyeth pulls cold remedies for kids

Here's a perfect example of the dose-related confusion that has pediatrics experts calling for action against cold meds for kids: More than a half dozen Wyeth products now on store shelves have dosage cups that lack the mark for a half-teaspoon. That's the proper amount for children 2 to 5. The Robitussin and Dimetapp products won't be on shelves for long, though. Wyeth is recalling them to replace their cups with an updated version.

Just three weeks ago, drug makers recalled cold and cough meds for kids under two. Then, an FDA advisory committee hashed over safety and efficacy of these remedies for kids under six--and finally concluded that they shouldn't be used. The agency is now deciding what comes next.

- take a look at this news release from Wyeth
- read the AP article

Related Articles:
FDA panel: No cold meds for under-6 kids. Report
FDA experts mull ban on child cold meds. Report
Drug makers recall infant cold meds. Report
FDA to review OTC cough medicine safety. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.